Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Novartis CEO discusses search for obesity deals with WSJ
CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...
News Highlights: Top Company News of the Day - Tuesday at 1 PM ET
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...
pharmaphorum5d
Digital Health Round-Up: Novartis and Science 37 hope to cut R&D costs
Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...
pharmaphorum5d
Novartis oncology CEO quits after less than a year
Novartis CEO Vas Narasimhan said: "I would like to thank Liz for her leadership and her contributions to our business and our patients this past year. She made a significant positive impact on the ...
pharmaphorum4d
Novartis names ex-BMS CEO Caforio as chair amid strong Q1
The news sparked a near-5% rise in Novartis’ share price. Chief executive Vas Narasimhan said performance ... be considering an M&A push. The ex-BMS CEO was the architect of some massive deals ...
pharmaphorum6d
Novartis decides Sandoz' future – and it's a spin-out
although Novartis chief executive Vas Narasimhan said this morning he would still consider bids for the business. Sandoz CEO Richard Saynor will remain at the helm of the business following the ...